Last10K.com

Alseres Pharmaceuticals Inc De (ALSE) SEC Filing 10-Q Quarterly report for the period ending Monday, September 30, 2013

Alseres Pharmaceuticals Inc De

HISTORY TOOLS
CIK: 94784 Ticker: ALSE
Document and Entity Information
 9 Months Ended
Sep. 30, 2013
Oct. 31, 2013
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2013  
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q3  
Entity Registrant Name ALSERES PHARMACEUTICALS INC /DE  
Entity Central Index Key 0000094784  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   30,635,720

View differences made from one quarter to another to evaluate Alseres Pharmaceuticals Inc De's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alseres Pharmaceuticals Inc De.

Continue

Assess how Alseres Pharmaceuticals Inc De's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Alseres Pharmaceuticals Inc De's Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Statements Of Comprehensive Loss
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Accounting For Stock-based Compensation
Accounting For Stock-based Compensation (tables)
Accounting For Stock-based Compensation - Additional Information (detail)
Accounting For Stock-based Compensation - Summary Of Outstanding Stock Options (detail)
Accounting For Stock-based Compensation - Summary Of Stock Options Outstanding And Exercisable (detail)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (tables)
Accounts Payable And Accrued Expenses - Additional Information (detail)
Accounts Payable And Accrued Expenses - Summary Of Accounts Payable And Accrued Expenses (detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (detail)
Convertible Preferred Stock
Convertible Preferred Stock - Additional Information (detail)
Fair Value Measurements
Fair Value Measurements (tables)
Fair Value Measurements - Additional Information (detail)
Fair Value Measurements - Summary Of Financial Asset Measured At Fair Value (detail)
Income Taxes
Income Taxes - Additional Information (detail)
Nature Of Operations And Basis Of Presentation
Nature Of Operations And Basis Of Presentation - Additional Information (detail)
Net Loss Per Share
Net Loss Per Share - Additional Information (detail)
Notes Payable And Debt
Notes Payable And Debt (tables)
Notes Payable And Debt - Additional Information (detail)
Notes Payable And Debt - Summary Of Notes Payable To Significant Stockholder (detail)
Notes Payable And Debt - Summary Of Notes Payable To Significant Stockholder (parenthetical) (detail)
Related Party Transaction
Related Party Transaction - Additional Information (detail)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies - Additional Information (detail)
Ticker: ALSE
CIK: 94784
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-13-442102
Submitted to the SEC: Thu Nov 14 2013 4:02:23 PM EST
Accepted by the SEC: Thu Nov 14 2013
Period: Monday, September 30, 2013
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/alse/0001193125-13-442102.htm